<SEC-DOCUMENT>0001157523-22-000302.txt : 20220308
<SEC-HEADER>0001157523-22-000302.hdr.sgml : 20220308
<ACCEPTANCE-DATETIME>20220308080141
ACCESSION NUMBER:		0001157523-22-000302
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220308
FILED AS OF DATE:		20220308
DATE AS OF CHANGE:		20220308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		22720366

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52591171.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div>&#160;&#160; <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: center;">For the month of March 2022</div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
      <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
      <div style="text-align: center;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="text-align: center;">Form 20-F&#160; &#9744; Form 40-F&#160; &#9746;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <div>
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="text-align: center;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z22a7733253784d9a960b79405e30b511" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 13%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 85%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div><a href="a52591171_ex991.htm">99.1</a></div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 85%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify;"><a href="a52591171_ex991.htm">Press Release dated March 08, 2022.</a></div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; margin-top: 6pt; font-weight: bold;">&#160;SIGNATURE</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z38de9459cc1b49508efe57a0a19e95e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
              <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Date: March 08, 2022</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-style: italic;">/s/ Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160; <br>
      </div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52591171_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <div class="bw-release">
        <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET</b> </h1>
        <div class="bw-release-body">
          <div class="bw-release-table-js bw-release-story">
            <p>VICTORIA, British Columbia--(BUSINESS WIRE)--March 8, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced
              today announced that it will host a conference call to discuss its financial results and recent business highlights for third quarter fiscal year 2022, on Wednesday, March 16<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, 2022, at 10:30 a.m. ET. The financial results will be
              issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. </p>
            <p> Investors interested in submitting questions ahead of the call are encouraged to email John Mullaly of LifeSci Advisors, the Company&#8217;s investor relations contact. </p>
            <p> <b>Earnings Call Details:</b> </p>
            <p> <b>Date:</b> March 16, 2022 <br>
              <b>Time:</b> 10:30 a.m. Eastern time <br>
              <b>Toll-free dial-in number:</b> 1-877-407-3982 <br>
              <b>International dial-in number:</b> 1-201-493-6780 <br>
              <b>Conference ID:</b> 13727621 <br>
              <b>Webcast:</b> https://viavid.webcasts.com/starthere.jsp?ei=1534157&amp;tp_key=1be5e34d32<br>
              The conference call will be webcast live and available for replay via a link provided in the Investors section of the company&#8217;s website at https://www.immunoprecise.com/investors/. </p>
            <p> Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. </p>
            <p> Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations
              and financial condition in those reports. </p>
            <div> </div>
            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> <b>ImmunoPrecise Antibodies Ltd. <br>
              </b>ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to
              transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging
              epitopes. For further information, visit www.immunoprecise.com. </p>
          </div>
          <div class="bw-release-contact">
            <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
            <p> <b>Investors: </b><br>
              <b>LifeSci Advisors </b><br>
              John Mullaly <br>
              jmullaly@lifesciadvisors.com </p>
          </div>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
